Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

DEXmedetomidin for postoperativ analgetika og deliriumforebygging etter NEVROkirurgi (DEX-NEVRO-studien) (DEX-NEURO)

4. november 2026 oppdatert av: Ka Ting Ng, University of Malaya

DEXmedetomidin for postoperativ analgetika og deliriumforebygging etter NEUROkirurgi: En dobbeltblind randomisert placebo-kontrollert studie (DEX-NEURO-studien)

Post-craniotomy pain is common and often undertreated. Inadequate analgesia can lead to patient discomfort and higher opioid consumption, which may result in respiratory depression, sedation risks and impaired neurological assessment in the early postoperative period. The incidence of post-operative delirium after intracranial surgery was 19%, ranging from 12 to 26% caused by variation in clinical features and delirium assessment methods1. It is associated with increased morbidity, longer length of hospital stay, and harm to self or staffs.

Dexmedetomidine (Precedex) is a highly selective α2-adrenergic agonist with the properties of analgesia, sedative, anxiolytic and neuroprotection without significant respiratory depression. Most of the trials administered a loading dose of 0.5-1.0 μg/kg intravenous dexmedetomidine over 10 minutes followed by infusion dose 0.2-0.7 μg/kg/hour. The use of intraoperative dexmedetomidine is believed to reduce the usage of postoperative opioids where frequent neurological assessment is often required in neurosurgical patients. Beyond the benefit of analgesia, perioperative dexmedetomidine has been studied for prevention of postoperative delirium. Randomized trials in mixed noncardiac surgical populations reported that low-dose perioperative dexmedetomidine may reduce the incidence of delirium. Dexmedetomidine produces dose-dependent bradycardia and hypotension, which should be carefully monitored to maintain the cerebral perfusion pressure in brain surgery. However, most trials and meta-analyses have focused on general surgical or cardiac cohorts; the evidence remains limited in neurosurgical (craniotomy) patients.

Although it showed promising benefits of analgesia and neuroprotection in non-neurosurgical patients, recent meta-analyses of intraoperative dexmedetomidine reported high degree of heterogeneity due to the inclusion of varied procedures (elective vs emergent craniotomy), dosing regimes (loading dose only versus loading dose + infusion versus infusion only) and varied primary endpoints (postoperative pain scores, cumulative opioid consumption or incidence of delirium). Therefore, this randomized, double-blind, placebo-controlled trial is designed to examine the use of intravenous dexmedetomidine in the reduction of postoperative pain score and delirium in neurosurgical patients. We hypothesised that intravenous dexmedetomidine reduces postoperative pain score and delirium with lower need of rescue analgesia and amount of morphine consumption in patients undergoing craniotomy.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

There are several similar studies been conducted in the literature search. However, the majority of the studies focus on the intensive care unit patient or non-neurosurgery patients. It is believed that intravenous dexmedetomidine can reduce the postoperative pain score with lesser need for rescue analgesia and morphine consumption to facilitate postoperative neurological assessment.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • All adult (American Society of Anaesthesiologists (ASA 1-2) who >18 years old and <65 years old undergoing elective craniotomy

Exclusion Criteria:

  • Patients who are ASA 3-5 or BMI <18/ >40 or allergic to dexmedetomidine will be excluded. Patients with high-grade heart block or uncontrolled bradyarrhythmia will also be excluded.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Intravenous dexmedetomidine

Intravenous dexmedetomidine loading dose 0.5mcg/kg followed by 0.5mcg/kg/hour

intravenous dexmedetomidine loading dose 0.5mcg/kg followed by 0.5mcg/kg/hour

Andre navn:
  • Precedex
Placebo komparator: Intravenous normal saline

intravenous normal saline loading and infusion dose

Intravenous normal saline loading and infusion dose of normal saline

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Postoperative pain score at recovery area
Tidsramme: In the recovery area after pushing out from the operation theatre (Post-operative 1-hour, Day 1, Day 2)

Numerical Rating Scale (0 no pain-10 most pain)

In the recovery area after pushing out from the operation theatre (Post-operative 1-hour, Day 1, Day 2)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Need of rescue analgesia
Tidsramme: In the recovery area after pushing out from operation theatre (Post-operative 1-hour)

Need to receive additional analgesia (bolus of ketamine, fentanyl, morphine) in the recovery area

In the recovery area after pushing out from operation theatre (Post-operative 1-hour)
Total usage of postoperative morphine use in the first 24-hour
Tidsramme: In the first 24-hour after surgery in neurointensive care unit

The amount of morphine usage in milligram

In the first 24-hour after surgery in neurointensive care unit
Postoperative nausea or vomiting
Tidsramme: Within the first 24-hour in neurointensive care unit

Incidence of nausea or vomiting in the first 24-hour in neurointensive care unit

Within the first 24-hour in neurointensive care unit
Incidence of delirium
Tidsramme: Day-1 and Day-2 in neurointensive care unit

Assessed by CAM-ICU scoring test

Day-1 and Day-2 in neurointensive care unit
Patient satisfaction scale of analgesia control
Tidsramme: Day-1 in neurointensive care unit

Numerical rating scale (0 not satisfy - 10 very satisfy)

Day-1 in neurointensive care unit
Adverse events of dexmedetomidine (hypotension and bradycardia).
Tidsramme: During surgery when intravenous dexmedetomidine is started

systolic blood pressure < 90, heart rate <60

During surgery when intravenous dexmedetomidine is started

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

22. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

26. januar 2026

Først innsendt som oppfylte QC-kriteriene

2. februar 2026

Først lagt ut (Faktiske)

9. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere